①文獻(xiàn)和網(wǎng)站來源必須權(quán)威、專業(yè)，盡量找外文或官網(wǎng)的文獻(xiàn)或報(bào)道，不能是百度百科等； ②簡(jiǎn)要概述的語句具有邏輯性和連貫性。 ③由于藥物本身存在信息不全或難找到信息源，以及藥物概述質(zhì)量不定（如翻譯質(zhì)量不定等）的情況，賞金酌情給出，請(qǐng)諒解。 ④單價(jià)8元/條，質(zhì)量偏低需折價(jià)計(jì)算。 32個(gè)合格5個(gè)內(nèi)容偏少，32*8+5*4=276 *此任務(wù)金額為不含稅金額，按照國(guó)家稅務(wù)相關(guān)法律法規(guī)，提現(xiàn)時(shí)個(gè)稅由藥智匯代扣代繳   [更多]

1、Ophthalmic viscosurgical devices Article· Literature Review?in?Current Opinion in Ophthalmology 19(1):50-4 · February 2008?with?82 Reads DOI: 10.1097/ICU.0b013e3282f14db0 · Source: PubMed 2、Lancet Psychiatry. 2019 Mar;6(3):211-224. doi: 10.1016/S2215-0366(18)30511-X. Epub 2019 Feb 18. Prevalence of mental disorders in China: a cross-sectional epidemiological study. Huang Y1, Wang Y2, Wang H3, Liu Z4, Yu X4, Yan J5, Yu Y6, Kou C6, Xu X7, Lu J7… PMID:30792114 3、Prevalence of myopia in local and international schools in Hong Kong. 4、Effects of different concentrations of atropine on controlling myopia in myopic children. 5、Effects of muscarinic cholinergic receptor antagonists on postnatal eye growth of rhesus monkeys 6、Effects of different concentrations of atropine on controlling myopia in myopic children. 7、Use of mechlorethamine gel in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): “Real-world” experience from the Prospective Observational Study (PROVe) 8、Safety and effectiveness of tolvaptan administration after total arch replacement Yasunori Iida, MD, PhD, Akihiro Yoshitake, MD, PhD, Hideyuki Shimizu, MD, PhD 9、The role of tolvaptan administration after cardiac surgery: ameta-analysisIoannis Bellos MD , Dimitrios C. Iliopoulos MD, PhD ,Despina N. Perrea MD, PhD 10、Comparative bioavailability and in vitro in vivo correlation of two sustained release brands of theophylline: tablets and pellets.Tulain U, Ur-Rahman N.Pak J Pharm Sci. 2008 Apr;21(2):131-8. 11、Relative bioavailability and bioequivalence study of theophylline sustained release formulations. Vergin H, Mahr G, Winterhalter B, Wigand R.Arzneimittelforschung. 2003;53(9):635-9. 12、Use of mechlorethamine gel in patients diagnosed with mycosis fungoides cutaneous T-cell lymphoma (MF-CTCL): “Real-world” experience from the Prospective Observational Study (PROVe) 13、journal of medicinal chemistry 2004,47,530 14、Gupta AK, Ryder JE, Lynch LE et al. The use   [更多]

文獻(xiàn)： 1、Journal of Organic Chemistry1961vol. 26p. 2507 - 2510 2、J Contemp Dent Pract. 2016 Dec 1;17(12):1009-1012.Rebamipide to Manage Stomatopyrosis in Oral Submucous Fibrosis.Baptist J1, Shakya S2, Ongole R1. 3、heart failure with preserved ejection fraction：types 1 and 2 ？10.1016/j.jchf.2018.12.017 4、Current status of research on infantile cholestatic liver disease in China: a visualization analysis Author(s): LIAO Qiong, WAN Chao-Min, ZHU Yu, YANG Xiao-Yan, SHU Min, Department of Pediatrics, West China Second University Hospital, Sichuan University/Key Laboratory of Birth Defects and Related Diseases of Women and Children, Ministry of Education, Sichuan University 5、Diagnosis and differential diagnosis of infantile cholestasis disease Author(s): Dong Chen, Huang ZhihuaDong Chen: Department of Pediatrics, Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology, Wuhan 430030, China 6、In vitro dissolution and in vivo bioequivalence evaluation of two brands of isosorbide 5-mononitrate sustained release tablets.Kim YH1, Choi KS, Kam SH, Lee KH, Park JS 7、Evaluation of the bioequivalence and pharmacokinetics of two tablet formulations of isosorbide-5-mononitrate after single oral administration in healthy volunteers. Niopas I1, Daftsios AC, Nikolaidis N. 8、PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial；（新型口服碳青霉烯類抗生素替比培南匹伏酯（ME1211）在耳鼻咽喉感染中的pk/pd分析，一項(xiàng)Ⅱ期臨床試驗(yàn)） 9、PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial；（新型口服碳青霉烯類抗生素替比培南匹伏酯（ME1211）在耳鼻咽喉感染中的pk/pd分析，一項(xiàng)Ⅱ期臨床試驗(yàn)） 10、Trends in the Management of Acute Heart Failure Requiring Intensive Care Shirakabe A Kobayashi N, kazakh Matsushita M, Shibata Y -, Godah, Shigihara s", AsanKiuchit 11、Patient Selection for Tolvaptan Therapy Among Those With Chronic Kidney Disease and Heart Failure 12、Baumann;?Butler;   [更多]

新版醫(yī)保目錄需求說明書。   [更多]

DrugsoftheFuture（DOF）2022年1-3期 文獻(xiàn)必須完整、準(zhǔn)確（備注：此任務(wù)已線下聯(lián)系好）   [更多]

DrugsoftheFuture（DOF）2020年8-10期 文獻(xiàn)必須完整、準(zhǔn)確   [更多]

1.Nihon Yakurigaku Zasshi. 2013 Jul;142(1):39-46. doi: 10.1254/fpj.142.39. Pharmacological and clinical properties of AIMIX combination tablets LD&HD, fixed-dose combination of irbesartan and amlodipine besilate. 2.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 3.Clin Ther. 2012 Aug;34(8):1705-19. doi: 10.1016/j.clinthera.2012.06.026. Epub 2012 Jul 30. I-COMBINE study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with amlodipine monotherapy in hypertensive patients uncontrolled with amlodipine 5 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 4.Clin Ther. 2012 Aug;34(8):1720-34.e3. doi: 10.1016/j.clinthera.2012.07.001. Epub 2012 Jul 30. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study. 5.Am J Cardiovasc Drugs. 2013 Apr;13(2):141-50. doi: 10.1007/s40256-013-0014-7. Irbesartan/amlodipine: a review of its use in adult patients with essential hypertension not adequately controlled with monotherapy. 6J Cardiol. 2019 Mar 20. pii: S0914-5087(19)30053-X. doi: 10.1016/j.jjcc.2019.03.001. [Epub ahead of print] Arginine vasopressin antagonism in heart failure: Current status and possible new directions. Goldsmith SR1. 7.Metabolism of Peptide Drugs and Strategies to Improve their Metabolic Stability 8.Expert Rev Neurother. 2017 Jan;17(1):59-75. Epub 2016 Oct 20. Modulation of GLP-1 signaling as a novel therapeutic approach in the treatment of Alzheimer's disease pathology. Tramutola A1, Arena A1,   [更多]

具體要求： 1、查找藥品信息，補(bǔ)充完整藥品對(duì)應(yīng)的所有靶點(diǎn)信息和查找的數(shù)據(jù)來源網(wǎng)址。藥物與機(jī)體生物大分子的結(jié)合部位即藥物靶點(diǎn)。藥品作用的靶點(diǎn)信息涉及受體、酶、離子通道、轉(zhuǎn)運(yùn)體、基因、免疫系統(tǒng)等類型。 2、文獻(xiàn)或者網(wǎng)站來源必須權(quán)威、專業(yè)，需是直接能看到靶點(diǎn)信息的網(wǎng)址或者文章，不能是百度百科； 3、靶點(diǎn)的信息需完整，靶點(diǎn)的寫法需是全稱加簡(jiǎn)稱； 4、一共83條，單價(jià)10元/條，一人完成，共計(jì)830元，若在來源中核查不到該藥品對(duì)應(yīng)的靶點(diǎn)信息，或者查找不到，該條的懸賞金則扣除，望諒解； 5、完成日期2021年6月4日。 有意者聯(lián)系本人，聯(lián)系方式：（微信:qqsslalala;QQ:158224259） 后期會(huì)有相同的懸賞任務(wù)發(fā)布，期待一人長(zhǎng)期合作。 *此任務(wù)金額為不含稅金額，按照國(guó)家稅務(wù)相關(guān)法律法規(guī)，提現(xiàn)時(shí)個(gè)稅由藥智匯代扣代繳。   [更多]

ID：嘻嘻嘻嘿嘿嘿，領(lǐng)取賞金；處理統(tǒng)計(jì)之后藥智網(wǎng)未收載的說明書數(shù)量為23條，已收載的說明書條數(shù)為47條，總的賞金=23*5+47*3=256   [更多]

①文獻(xiàn)和網(wǎng)站來源必須權(quán)威、專業(yè)，盡量找外文或官網(wǎng)的文獻(xiàn)或報(bào)道，不能是百度百科等； ②簡(jiǎn)要概述的語句具有邏輯性和連貫性。 ③由于藥物本身存在信息不全或難找到信息源，以及藥物概述質(zhì)量不定（如翻譯質(zhì)量不定等）的情況，賞金酌情給出，請(qǐng)諒解。 ④單價(jià)8元/條，質(zhì)量偏低需折價(jià)計(jì)算。 26個(gè)合格，11個(gè)內(nèi)容偏少，26*8+11*4=252 *此任務(wù)金額為不含稅金額，按照國(guó)家稅務(wù)相關(guān)法律法規(guī)，提現(xiàn)時(shí)個(gè)稅由藥智匯代扣代繳   [更多]